Argenx wins second FDA approval for Vyvgart in autoimmune nerve disease

Ryan Cross

Senior Science Correspondent

After a string of clinical failures, the Dutch biotech argenx landed a much-needed win on Friday when the FDA approved its autoimmune disease drug, Vyvgart …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Argenx wins second FDA approval for Vyvgart in autoimmune nerve disease

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

FDA rejects Daiichi Sankyo's HER3 ADC, a blow to quick approval plans for Merck partnership

AbbVie buys Third Rock's Celsius for $250M to expand IBD pipeline

Maze spins its ALS antisense program into a secretive new company

Q&A: Vertex’s pain research chief on moving beyond opioids, AI and how pharma acquisitions thrive or fail

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Ar­genx wins sec­ond FDA ap­proval for Vyv­gart in au­toim­mune nerve dis­ease

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

more like this

Bio­gen is pur­su­ing more deal­mak­ing this year, with plans to spend up to $8B

FDA re­jects Dai­ichi Sanky­o's HER3 ADC, a blow to quick ap­proval plans for Mer­ck part­ner­ship

Ab­b­Vie buys Third Rock­'s Cel­sius for $250M to ex­pand IBD pipeline

Maze spins its ALS an­ti­sense pro­gram in­to a se­cre­tive new com­pa­ny

Q&A: Ver­tex’s pain re­search chief on mov­ing be­yond opi­oids, AI and how phar­ma ac­qui­si­tions thrive or fail

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

Argenx wins second FDA approval for Vyvgart in autoimmune nerve disease

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

FDA rejects Daiichi Sankyo's HER3 ADC, a blow to quick approval plans for Merck partnership

AbbVie buys Third Rock's Celsius for $250M to expand IBD pipeline

Maze spins its ALS antisense program into a secretive new company

Q&A: Vertex’s pain research chief on moving beyond opioids, AI and how pharma acquisitions thrive or fail

Scientists unveil new way to make large changes to genes, and no CRISPR is required